B O A R D O F D I R E C T O R S
C A M E R O N P I R O N
Chairman and Director
Cameron Piron is an industry-recognized leader and innovator in
image-guided surgery. Prior to co-founding Synaptive Medical,
Cameron was president and co-founder of Sentinelle Medical, a
medical device company that developed and manufactured advanced
MRI-based breast imaging technologies. Sentinelle grew to over 200
employees and over $20 million in revenues before being acquired by
Hologic, Inc. in 2010. Cameron studied systems design engineering
at the University of Waterloo, followed by a graduate degree at the
University of Toronto in medical biophysics. His awards include the
Ontario Premier’s Catalyst Award for Best Young Innovator in 2008;
the University of Waterloo’s Alumni Achievement medal in 2009 for
leading Sentinelle Medical in researching and manufacturing leading-
edge MRI technologies that allow physicians to diagnose breast
cancer and other medical conditions faster and more accurately;
being named to Canada’s Top 40 Under 40™ list in 2009, which was
established by Caldwell Partners and celebrates the achievements of
young Canadians in the private, public and non-profit sectors; and
being the first Canadian ever to win R&D Magazine’s Innovator of
the Year award in 2008. In 2015, Cameron was named one of Fast
Company’s Most Creative People. He chairs Synaptive’s Board of
Directors and heads the company’s executive committee.
MKT-00612 Rev. A
R I C H A R D B U T L A N D
Director
Richard Butland is the managing partner of Kite Capital, a growth
orientated private investment firm. Prior to establishing Kite Capital,
Richard spent 15 years at Goldman Sachs. He joined Goldman
Sachs in 2000 in the UK Advisory Group and was named managing
director in 2006. He ran the UK M&A Advisory business in 2007
and subsequently moved to the Merchant Banking Division to head
its private equity activities in the UK and Energy across Europe.
Richard worked at IBJ Schroder Bank and PricewaterhouseCoopers
prior to Goldman Sachs. He earned a bachelor’s degree in finance
from Victoria University of Wellington and qualified as a chartered
accountant.
D AV I D C A L U O R I
Director
David Caluori joined General Atlantic as a principal in 2014 where
he focuses on investments in the healthcare sector. Prior to joining
General Atlantic, David was with Welsh, Carson, Anderson & Stowe,
where he focused exclusively on investments in the healthcare sector.
He began his career in healthcare investment banking at Piper Jaffray
and Jefferies. David is on the board of Oak Street Health and received
a bachelor of arts in economics from Brown University.
D AV I D G A L L O P
Director
David Gallop has 15 years of experience in medical software
development. He graduated with a B.A.Sc. in Electrical Engineering
from McGill University in 2000 and began his career at eFilm Medical,
remaining on board for two years following its acquisition by Merge
Healthcare. David then joined Sentinelle Medical and was one of the
primary architects of its Aegis Breast diagnostic software. Following
Sentinelle’s acquisition by Hologic, Inc., David co-founded Synaptive
Medical, and is now focused on the architecture and development of
Synaptive’s BrightMatter suite of software products.
MKT-00612 Rev. A
D O U G J A N Z E N
Director
Doug Janzen brings over 20 years of experience in life sciences
to Synaptive’s Board of Directors with leadership experience in
corporate finance, business development, and management. During
his nine-year tenure at Cardiome Pharma (NASDAQ: CRME), Doug held
a series of positions including chief financial officer (2003 to 2005),
president and chief business officer (2005 to 2009), and president
and CEO (2009 to 2012). During this time, he raised over C$300
million from investors, completed over C$1 billion in licensing deals,
and led a partnership with Merck to bring Cardiome’s lead product,
Brinavess, through to clinical approval and marketing in Europe.
Doug is currently co-founder and managing director of NorthView
Ventures, chairman and CEO of Aequus Pharmaceuticals, and serves
on the Boards of Aequus Pharmaceuticals, Alabaster Technologies,
Abcellera (chairman), Ico Therapeutics, Perimeter Medical Imaging, and
Renaissance Biosciences. Prior to Cardiome, Doug was an investment
banker with Cormark Securities, acting as managing director of life
sciences, and has completed over C$1 billion in equity financing for
Canadian biotech companies. Doug is past chair of LifeSciences BC,
has served as a director with Biotech Canada and is a past winner of
Business in Vancouver’s “Top 40 Under 40 Award.”
W E S H O D G E S
Director
Wes Hodges graduated from the University of Toronto’s Engineering
Science program in 2003. In 2001, he began his career in medical
imaging at eFilm Medical. Following its acquisition by Merge
Healthcare in 2002, Wes formed Sentinelle Medical’s software
division in 2005, developing its 3D Aegis Breast diagnostic and
interventional platform. A few years following Sentinelle’s acquisition
by Hologic, Inc. in 2010, Wes co founded Synaptive Medical where
he focuses on developing a unifying software framework across its
various products.
MKT-00612 Rev. A
A N D R E W P R O Z E S
Director
Andrew Prozes currently serves on the boards of Transunion, Cott
Corporation, Corporate Risk Holdings (CRH), Asset International,
Synaptive Medical, payfone, Scribestar and Ethoca. He chairs
the Human Resources & Compensation Committee for Cott, and
also chairs the Compensation Committees for Transunion, Ethoca
and CRH. Andrew has served on not-for-profit boards including
the CEELI Institute, the Bruce Museum in Greenwich, CT, and the
Executive Committee of The Atlantic Council in Washington, D.C.
From 2000 to 20111, Andrew was CEO of LexisNexis and served on
the board of directors of Reed Elsevier. His past industry association
experiences include serving as chairman of The US Information
Industry Association and on the boards of the Information Technology
Association of Canada and the Canadian Newspaper Association.
Andrew graduated from University of Waterloo with a bachelor of
mathematics in computer science, and received his MBA from York
University.
G A L A S E L A
Secretary and Director
Gal Sela brings 18 years of experience in medical imaging to
Synaptive. He has a background in electrical engineering and a
master’s degree in computer vision from McGill University. Gal began
his career in medical imaging as part of a Toronto Western Hopsital
(IGMIT) team involved in the intra-operative MRI system, where he
played a role from the early installation phases of the system and
supported neurosurgical procedures throughout its operational life.
Gal also developed the intra-operative, image-guided navigation
system that was used in conjunction with the IGMIT system. Other
research directions included detecting white matter disease, diffusion
fiber tractography, and lesion segmentation and classification. Prior
to co-founding Synaptive, Gal was co-founder and CTO of Sentinelle
Medical, where he oversaw the development of innovative imaging
technologies for breast and prostate cancer detection, including an
image-guided navigation system that integrated MRI with ultrasound
imaging and registration to soft tissue.
MKT-00612 Rev. A
P E T E R W E H R LY
Director
Until recently, Peter Wehrly was group president developed markets
at Covidien, the manufacturer of medical devices with sales of over
$10.7 billion (2014). Peter held profit and loss responsibility for the
marketing and sale of products to all developed markets outside
the U.S. between 2013 and 2015. The division had sales of over
$3.9 billion, and accounted for 34 percent of global revenue and 62
percent of global operating income. He departed following the $42
billion sale of Covidien to Medtronic in 2015. Prior to this role, Peter
was the president of Respiratory and Monitoring Solutions. He led
the division’s turnaround from a negative revenue growth rate of -4.3
percent in 2009 to +3.5 percent in 2010. He was also responsible for
Covidien’s Japanese, Australia-New Zealand and Canadian businesses.
Between 2008 and 2009 Peter was the president and CEO of Medingo
Youqneam, an Israel-based technical team that was developing a novel,
low-cost, patient benefit-rich insulin pump for Type I and II diabetic
patients. He optimized the business, resulting in its ultimate sale to
Roche. Previously, Peter held leadership positions at Medtronic in their
Spinal and Biologics business where he oversaw revenue growth from
approximately $500 million to $2.8 billion in five years. He started his
career with DePuy, a Johnson & Johnson company.
MKT-00612 Rev. A